2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2020-6-2-0-62041Pharmacology<strong>A study of neuroprotective properties of the MGLUR4 receptor agonist &ndash; ZC64-0001 in comparison with Mexidol</strong><br /> &nbsp;<strong>A study of neuroprotective properties of the MGLUR4 receptor agonist &ndash; ZC64-0001 in comparison with Mexidol</strong><br /> &nbsp;AvdeevaNatalia V.AvdeevaNatalia V.7400468@mail.ru20206200

Background:&nbsp;One of the most common neurodegenerative diseases is Parkinson&#39;s disease, which is based on the degeneration of dopaminergic neurons of the substantia nigra. The modern treatment for Parkinson&#39;s disease is a dopamine replacement therapy with levodopa, the use of which does not lead to a stop, progressive neurodegeneration and causes the appearance of side effects. Glutamate metabotropic receptors (mGluRs) are a promising application point for the search for new anti-Parkinsonian drugs. Group III metabotropic receptors are able to reduce the activity of NMDA receptors involved in the regulation of calcium levels in cells. Therefore, it is suggested that activation of these receptors may have a neuroprotective effect. The mGluR4 receptor agonist was synthesized at the &laquo;ChemRar&raquo;. Further studies of the substance were carried out at the Scientific Research Institute &quot;Pharmacology of Living Systems&quot;, BSU (Belgorod). The aim of the study:&nbsp;To study the neuroprotective efficacy of a pharmaceutical substance &ndash; ZC64-0001 in comparison with Mexidol in mice with cerebral ischemia. Materials and methods:&nbsp;The study was conducted on rats, divided into 9 groups of 10 animals. The test substance ZC64-0001 and the comparison drug Mexidol were administered intragastrically once a day for prophylactic and therapeutic purposes in various dosages. Then, the behavioral responses of animals were evaluated before the simulation of the IHM and on days 2, 7, and 14 after; level S100b and NSE after the cerebral ischemia. Results:&nbsp;In the course of the study it was found that the use of ZC64-0001 and Mexidol in the studied doses had a pronounced neuroprotective effect, manifested in a decrease in the severity of neurological deficit; and accelerating the disappearance of the symptoms of paralysis, ptosis, etc. At the same time, an improvement in motor activity indicators in the PLC and actimetry test was found, as well as a significant prevention of an increase in NSE and S100b protein. Conclusion:&nbsp;The neuroprotective effect of the mGluR4 receptor agonist is explained by their ability to reduce the activity of the NMDA receptor and, therefore, the risk of excitotoxicity.

Background:&nbsp;One of the most common neurodegenerative diseases is Parkinson&#39;s disease, which is based on the degeneration of dopaminergic neurons of the substantia nigra. The modern treatment for Parkinson&#39;s disease is a dopamine replacement therapy with levodopa, the use of which does not lead to a stop, progressive neurodegeneration and causes the appearance of side effects. Glutamate metabotropic receptors (mGluRs) are a promising application point for the search for new anti-Parkinsonian drugs. Group III metabotropic receptors are able to reduce the activity of NMDA receptors involved in the regulation of calcium levels in cells. Therefore, it is suggested that activation of these receptors may have a neuroprotective effect. The mGluR4 receptor agonist was synthesized at the &laquo;ChemRar&raquo;. Further studies of the substance were carried out at the Scientific Research Institute &quot;Pharmacology of Living Systems&quot;, BSU (Belgorod). The aim of the study:&nbsp;To study the neuroprotective efficacy of a pharmaceutical substance &ndash; ZC64-0001 in comparison with Mexidol in mice with cerebral ischemia. Materials and methods:&nbsp;The study was conducted on rats, divided into 9 groups of 10 animals. The test substance ZC64-0001 and the comparison drug Mexidol were administered intragastrically once a day for prophylactic and therapeutic purposes in various dosages. Then, the behavioral responses of animals were evaluated before the simulation of the IHM and on days 2, 7, and 14 after; level S100b and NSE after the cerebral ischemia. Results:&nbsp;In the course of the study it was found that the use of ZC64-0001 and Mexidol in the studied doses had a pronounced neuroprotective effect, manifested in a decrease in the severity of neurological deficit; and accelerating the disappearance of the symptoms of paralysis, ptosis, etc. At the same time, an improvement in motor activity indicators in the PLC and actimetry test was found, as well as a significant prevention of an increase in NSE and S100b protein. Conclusion:&nbsp;The neuroprotective effect of the mGluR4 receptor agonist is explained by their ability to reduce the activity of the NMDA receptor and, therefore, the risk of excitotoxicity.

mGluR4 receptorsMexidolZC64-0001neuroprotectionmGluR4 receptorsMexidolZC64-0001neuroprotectionСписок литературыEspay AJ, Aybek S, Carson A, el al. Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurology. 2018;75(9):1132-1141. DOI: 10.1001/jamaneurol.2018.1264Avdeeva NV, Sidorova SA, Povetkin SV, el al. Positive allosteric modulation of mglur4 receptors as a potential approach to Parkinson&#39;s disease treatment proceedings of higher educational institutions. Medical Laboratory Sciences. 2018;3(47):194. DOI: https://doi.org/10.21685/2072-3032-2018-3-18Fabbri M,&nbsp;Coelho M,&nbsp;Abreu D,&nbsp;el al. Levodopa response in later stages of Parkinson&#39;s disease: A case-control study. Parkinsonism and Related Disorders. 2019;1353-8020(19):30470-5. DOI: 10.1016/j.parkreldis.2019.10.027Nicoletti F,&nbsp;Bockaert J,&nbsp;Collingridge G.L,&nbsp;el al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60(7-8):1017-1041. DOI: https://doi.org/10.1016/j.neuropharm.2010.10.022Zhang Z,&nbsp;Zhang S,&nbsp;Fu P,&nbsp;el al. Roles of Glutamate Receptors in Parkinson&#39;s Disease. International Journal of Molecular Sciences. 2019;20(18):4391. DOI: https://doi.org/10.3390/ijms20184391Klotz&nbsp;L,&nbsp;Wendler O,&nbsp;Frischknecht R,&nbsp;el al. Localization of group II and III metabotropic glutamate receptors at pre- and postsynaptic sites of inner hair cell ribbon synapses. FASEB Journal. 2019;33(12):13734-13746. DOI: https://doi.org/10.1096/fj.201901543RSpasov AA, Fedorchuk VU, Gurova NA, et al. Methodological approach to researching neuroprotective activity in experiment. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2014;4:39-45. Russian.Gannushkina IV.Cerebral circulation in different types of circulatory hypoxia of the brain. Annals of the Russian academy of medical sciences. 2000;9:22-27. Russian.Voronkov AV, Pozdnyakov DI. Endothelotropic activity of 4-hydroxy-3,5-di-tret-butylcinnamic acid in the conditions of experimental cerebral ischemia. Research Results in Pharmacology. 2018;4(2):1-10. DOI:10.3897/rrpharmacology.4.26519Avdeeva NV, Mechanism of neuroprotective effect of mGluR4 agonists. Research Results in Pharmacology. 2019;5(2):43-47. DOI: 10.3897/rrpharmacology.5.36565Domin H, Przykaza Ł, Jantas D, el al. Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies. Neuropharmacology. 2016;102:276-94. DOI: 10.1016/j.neuropharm.2015.11.025Yao L, Zhou Q. Neural Plasticity. 2017;2017:11. DOI: https://doi.org/10.1155/2017/2875904G&uuml;lcan HO, Orhan IE. The main targets involved in neuroprotection for the treatment of Alzheimer&#39;s Disease and Parkinson Disease. Current Pharmaceutical Design. 2020;26(4):509-516. DOI: https://doi.org/10.2174/1381612826666200131103524